上皮性卵巢癌hTERT表达及端粒酶活性的研究

目的探讨人端粒酶反转录酶(hTERT)表达及端粒酶活性与卵巢癌发生、发展的关系,评价其可否作为卵巢癌的肿瘤标志物及预后指标.方法应用RT-PCR及端粒重复扩增方法对43例上皮性卵巢癌、11例良性卵巢肿瘤和卵巢正常组织以及4例交界性卵巢肿瘤共69份标本进行hTERTmRNA及端粒酶活性检测.结果hTERT表达及端粒酶活性率在卵巢癌中分别为83.7%(36/43)及76.7%(33/43),良性肿瘤中均为9%(1/11),在正常卵巢组织和交界性卵巢肿瘤中阴性,其差异在卵巢癌与良性肿瘤及正常组织间均有显著性(P值分别为0.0004及0.0001).hTERT及端粒酶阳性率在某些预后因素如肿瘤类型、组织学分级、临床分期及肿瘤转移之间的差异皆无显著性.结论卵巢癌中存在高频率的hTERT表达及端粒酶激活,表明hTERT作为端粒酶的催化亚基,在肿瘤细胞端粒酶的激活中起关键作用.hTERT表达及端粒酶活性可望作为有价值的肿瘤标志物而用于卵巢癌的早期诊断,但其预后价值尚有待于进一步研究.     

食管鳞癌组织端粒酶亚基的表达及端粒酶活性的关系

目的　探讨食管鳞癌组织中端粒酶活性、端粒酶逆转录酶 (h TERT)及端粒酶相关蛋白 - 1(TP- 1)的表达及其关系。方法　应用 TRAP-银染法对 45例食管鳞癌组织端粒酶活性的检测 ,同时应用原位杂交对癌组织切片进行 h TERT、TP- 1的 m RNA表达的检测。结果　癌组织端粒酶活性阳性率为 82 .2 %。癌组织中不同分化程度的端粒酶活性差异无显著性 (P>0 .0 5 )。有淋巴结转移者癌组织端粒酶活性明显高于无淋巴结转移者 ,差异有显著性(P<0 .0 5 )。癌组织中 h TERTm RNA表达的阳性率为 6 4.4%,TP- 1的阳性率为 6 2 .2 %。 h TERT的 m RNA表达与端粒酶活性密切相关 ,而 TP- 1的 m RNA表达与端粒酶活性无相关。结论　食管鳞癌组织中端粒酶活性及h TERT、TP- 1的 m RNA表达均较高。端粒酶活性与淋巴结转移有关。 h TERT与端粒酶活性有密切关系。     

肝细胞癌端粒酶活性及hTERT mRNA表达与术后早期复发的关系

目的：研究肝细胞癌端粒酶活性及人端粒酶逆转录酶（hTERT）mRNA表达与肝细胞癌术后早期复发的关系。方法：采用ELISA—TRAP法检测60例肝癌组织及其癌旁组织端粒酶活性，RT—PCR法检测hTERT mRNA表达，5例正常肝脏组织作为对照。分析端粒酶活性及hTERT mRNA表达与临床病理之间的关系。结果：肝癌组织端粒酶活性及hTERT mRNA表达阳性率分别为86．7％（52／60）及90％（54／60），癌旁组织端粒酶活性及hTERT mRNA表达阳性率分别为40％（24／60）及43．3％（26／60）。正常肝脏组织均未检测到端粒酶活性及hTERT mRNA表达。癌旁组织端粒酶活性及hTERT mRNA表达与术后早期复发及包膜浸润、门静脉侵犯、肝内转移等恶性肿瘤的恶性生物学行为有关。结论：癌旁组织端粒酶活性及hTERT mRNA表达可能是肝细胞癌术后早期复发的预后指标。     

Differential telomerase activity, expression of the telomerase catalytic sub-unit and telomerase-RNA in ovarian tumors.

Telomerase activity has been found in a variety of malignant tumors but only rarely in benign tumors or normal tissues. In this study, we investigated telomerase activation in 37 ovarian tumors, including benign, borderline and malignant neoplasms. Telomerase activity was detected using the telomeric repeat amplification protocol (TRAP) in 13/16 ovarian carcinomas, 9/10 borderline tumors and 3/11 cystadenomas/fibromas. mRNA expression of the putative human telomerase catalytic sub-unit gene (hTERT) was detected by RT-PCR in 14/15 ovarian carcinomas, 8/10 borderline tumors and 4/11 cystadenomas/fibromas. In situ hybridization was performed to evaluate telomerase-RNA (hTR) expression in the corresponding paraffin-embedded tumors. Variable expression levels of hTR were found over neoplastic tumor cells. The highest levels of hTR expression were found predominantly in ovarian carcinomas. Although the amount of telomerase activity varied, significantly high levels of telomerase activity were found predominantly in ovarian carcinomas. hTERT mRNA expression was closely associated with telomerase activity. These findings suggest that up-regulation of hTERT and hTR is important for telomerase activation during malignant-tumor progression. Telomerase activation might therefore be a valuable diagnostic parameter that could help to identify potentially progressive lesions. However, the diagnostic and therapeutic implications of telomerase activation need to be clarified in clinical trials. Int. J. Cancer (Pred. Oncol.) 84:426-431, 1999.